Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

124.76 -2.28 (-1.79%)
Streaming Delayed Price Updated: 2:45 PM EDT, Jun 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
43 44 Next >
3 S&P 500 Stocks to Rival Nvidia’s 2023 Performance in the Second Half of 2024
Let’s explore three stocks that are well-positioned to rival Nvidia’s growth rates in the second half of 2024. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
Investors looking for good deals in the pharmaceutical industry should watch out for these three undervalued pharma stocks. 
Via InvestorPlace
Why Is Nuvo Group (NUVO) Stock Up 200% Today?
Although prenatal care specialist Nuvo Group saw its shares soar on Monday, NUVO stock faces skepticism over its SPAC merger. 
Via InvestorPlace
The Analyst Landscape: 27 Takes On Biogen
Via Benzinga
7 Retirement Stocks to Buy at a 52-Week Low in April
One of the best ways to keep your portfolio safe while generating income is with dividend-paying retirement stocks at 52-week lows. 
Via InvestorPlace
Topics Retirement
Exposures Pension
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Exposures US Equities
These Analysts Revise Their Forecasts On Biogen After Q1 Results
Via Benzinga
Where Biogen Stands With Analysts
Via Benzinga
Looking Into Biogen's Recent Short Interest
Via Benzinga
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser. 
Via Investor's Business Daily
Meta Platforms To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Why Biogen Stock Leaped Nearly 5% Higher Today
The company came out swinging with its first set of quarterly earnings for this year. 
Via The Motley Fool
Forecasting The Future: 18 Analyst Projections For Biogen
Via Benzinga
Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why
Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and concerns about efficacy and costs hinder widespread adoption despite FDA... 
Via Benzinga
Exposures Product Safety
Treasury Yields Rise, Tesla Jumps On Cheaper Model Pledge, Yen Plummets To 34-Year Lows: What's Driving Markets Wednesday?
Rising Treasury yields have investors cautious despite positive news from the earnings season. The yield on the long-dated 30-year Treasury bond has surged to 4.79%. It’s on track to close at the... 
Via Benzinga
Topics Bonds
Exposures Debt Markets
Biogen (BIIB) Q1 2024 Earnings Call Transcript
BIIB earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Biogen's Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings
Biogen reports Q1 results: adjusted EPS $3.67 (beat consensus), sales $2.29 billion (missed consensus). Leqembi launch uptake triples, Zurzuvae's early trends encouraging. 
Via Benzinga
BIIB Stock Earnings: Biogen Beats EPS, Misses Revenue for Q1 2024
BIIB stock results show that Biogen beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline?
Biogen shares have lost nearly 40% of their value since last June. Could two key sales beats help revive shares? 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Nasdaq Futures Get A Lift From Tesla, Texas Instruments Earnings: Analyst Points To Key Catalyst For Boosting Rally
Nasdaq and S&P 500 futures signaled a higher open on Wednesday, thanks to upbeat guidance from EV giant Tesla, Inc. (NASDAQ:TSLA) and semiconductor m 
Via Benzinga
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Big-Name Stocks Near 52 Week Lows: Are They A Buy?
Over the past twelve months, a number of big-name companies have been near or below their 52-week low price. Each week we’ll take a look at some of the biggest names currently close to their 52-week... 
Via Talk Markets
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
Exposures Product Safety
Tuesday Talk: Big-Tech Under Attack
On Thursday the Justice Dept. filed an antitrust suit against Apple. The suit joins two others already filed against Google. How much this will affect the market in the long run is up for grabs. 
Via Talk Markets
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom. 
Via InvestorPlace
European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab
Biogen and Eisai face delays as EMA postpones the oral explanation for the lecanemab review. Procedural issues at EMA prompt setback, impacting drug evaluation process amid recent EU court ruling. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Big-Name Stocks Near 52-Week Lows: Are They A Buy?
Over the past twelve months a number of big named companies have been near or below their 52 week low price. Each week we’ll take a look at some of the biggest names currently close to their 52 week... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
43 44 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.